glp-1 agonists and retained gastric contents at endoscopy & Receptor GLP-1 Gastroparesis: Hidden Dangers Beyond
Description
Clinician-written guides on GLP-1s, phentermine, metabolism, safe weight loss, and progress tracking
Weight Support*
Provider oversight and coaching included.
GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
